Provided herein are dendrimers comprising a core unit, five generations of building units being a lysine residue or analogue thereof, a plurality of first terminal groups each comprising a residue of a nucleoside analogue, and a plurality of second terminal groups each comprising a hydrophilic polymeric group. Also provided herein are pharmaceutical compositions comprising the dendrimer, and methods and uses of the dendrimers in therapy of disorders such as cancers.

The present invention provides peptoid polymers capable of reducing or inhibiting the formation of ice crystals at sub 0° C. temperatures. Also provided are peptoid-peptide hybrids comprising the peptoid polymers provided herein. The peptoid polymers and peptoid-peptide hybrids provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.

The present invention provides peptoid polymers capable of reducing or inhibiting the formation of ice crystals at sub 0° C. temperatures. Also provided are peptoid-peptide hybrids comprising the peptoid polymers provided herein. The peptoid polymers and peptoid-peptide hybrids provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.

The present disclosure is directed to novel lipidated poly(amino acid)s (LPAAs). The present disclosure is further related to processes for preparing such novel lipidated poly(amino acid)s (LPAAs) and for preparing novel lipidated poly(amino acid)s nanoparticles (LPAANPs). Additionally, the present disclosure relates to processes for utilizing lipidated poly(amino acid)s (LPAAs) that are biocompatible and capable of drug delivery.

The present disclosure is directed to novel lipidated poly(amino acid)s (LPAAs). The present disclosure is further related to processes for preparing such novel lipidated poly(amino acid)s (LPAAs) and for preparing novel lipidated poly(amino acid)s nanoparticles (LPAANPs). Additionally, the present disclosure relates to processes for utilizing lipidated poly(amino acid)s (LPAAs) that are biocompatible and capable of drug delivery.

A three-dimensional star-shaped α-helix polypeptide having a high-efficiency gene delivery capability, and a preparation method and an application thereof. A dendrimer is used as an initiator and dichloromethane is used as a reaction solvent to initiate high-speed ring-opening polymerization of different types of N-carboxylic anhydride monomers, and groups having different electrical properties are introduced at the ends via click chemistry reactions. The abundant amino groups on the surface of the dendrimer provide enough polymerization sites to enable the polypeptide to form a three-dimensional spherical topological structure, and the topological structure provides an opportunity for initial acceleration of the ring-opening polymerization reaction. The higher positive charge density caused by polypeptide side chain modified guanidine/amino groups etc. achieves a high-efficiency gene loading capability by the electrostatic effect between positive and negative charges, and the α-helix rigid structure on the secondary structure thus enables the polypeptide to have stronger membrane penetration capability.

The present disclosure provides methods of treating subjects having glaucoma or elevated intraocular pressure (IOP), methods of identifying subjects having an increased risk of developing glaucoma or developing elevated IOP, methods of detecting human Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) variant nucleic acid molecules and variant polypeptides, and ARHGEF12 variant nucleic acid molecules and variant polypeptides.

The present disclosure provides methods of treating subjects having glaucoma or elevated intraocular pressure (IOP), methods of identifying subjects having an increased risk of developing glaucoma or developing elevated IOP, methods of detecting human Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) variant nucleic acid molecules and variant polypeptides, and ARHGEF12 variant nucleic acid molecules and variant polypeptides.

A composition comprises, consists of, or consists essentially of a polymer including a derivatized amino acid monomer unit. A chemical mechanical polishing composition includes a water based liquid carrier, abrasive particles dispersed in the liquid carrier, and a cationic polymer having a derivatized amino acid monomer unit. A method of chemical mechanical polishing includes utilizing the chemical mechanical polishing composition to remove at least a portion of a metal or dielectric layer from a substrate and thereby polish the substrate.

The present invention relates to a chemical compound comprising (i) a polycationic polymer, coupled to (ii) a dye. The present invention further relates to a method for visualizing a glycosamine-containing structure in a biological sample comprising a) contacting an inner lumen of said biological sample with a dye-conjugated polycationic polymer, preferably with the chemical compound according to the present invention; b) tissue-clearing said biological sample; and, thereby, c) visualizing an internal glycosamine-containing structure in said biological sample. The present invention also relates to a method for determining the number and/or size of glomeruli in a kidney or a sample thereof making use of the method for visualizing a glycosamine-containing structure; and also relates to kits and uses related to said chemical compounds and said methods.